The Impact of PPAR𝜸 Genetic Variants on IBD Susceptibility and IBD Disease Course

Table 6

Impact of variant 12333125A>G on disease activity.

Category				12333125A>G
	Genotype	N ^(a)	N (%) of SNP carriers	OR (C.I.)	𝑃	OR (C.I.)^(b)	𝑃^(b)
Fistula	Het plus hom	83	15 (18.1)	1.24 (0.64–2.39)	0.52	1.25 (0.65–2.4)	0.51
No Fistula	Het plus hom	200	43 (21.5)
Fistula	hom	68	0 (0.0)	NA	1^(c)	NA	1
No Fistula	hom	159	2 (1.3)
EIM	Het plus hom	122	23 (18.9)	1.23 (0.68–2.21)	0.5	1.22 (0.67–2.21)	0.51
No EIM	Het plus hom	158	35 (22.2)
EIM	hom	100	1 (1.0)	0.81 (0.05–13.03)	1^(c)	0.87 (0.22–3.54)	0.85
No EIM	hom	124	1 (0.8)
Nonactive UC	Het plus hom	118	26 (22.0)	0.79 (0.25–2.53)	0.79	0.89 (0.27–2.96)	0.85
active UC^(d)	Het plus hom	22	4 (18.2)
NonActive UC	hom	93	1 (1.1)	NA	1^(c)	NA	1
active UC	hom	18	0 (0.0)
Quiescent CD	Het plus hom	94	17 (18.1)	1.51 (0.58–3.93)	0.4	1. 47 (0.56–3.88)	0.44
Acute CD^(d)	Het plus hom	32	8 (25.0)
Quiescent CD	hom	78	1 (1.3)	NA	1^(c)	NA	1
Acute CD	hom	24	0 (0.0)

N: absolute number; OR: odds ratio; CI: confidence interval; het: heterozygous; hom: homozygous; NA: not applicable; EIMs: extraintestinal manifestations ^(a)absolute number of subjects included into the respective analysis; ^(b)OR and 𝑃 value adjusted for age and sex; ^(c)𝑃 value calculated with Fisher’s exact test (otherwise Chi- Square test was used); ^(d) a threshold of CDAI = 150, and an mtwsi of 10 points was evaluated as the beginning of active disease.